Lenz Therapeutics Inc (LENZ) Stock Price, Quote & News

Company Profile

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7000

Website: www.lenz-tx.com

Address:

201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States

philipv777 Apr. 8 at 7:23 PM

$LENZ https://ir.lenz-tx.com/sec-filings/content/0001642575-26-000004/primary_doc.html

0 · Reply

JRobb66 Apr. 6 at 8:43 AM

$LENZ why is this stock in the toilet? Thought it had great expectations with a small float

2 · Reply

philipv777 Apr. 3 at 1:44 PM

$LENZ interesting off label use. The guy sounds like a set up for RD but good to see ophthalmologists are thinking about this drug

2 · Reply

prismmarketview Apr. 2 at 1:53 PM

We’re adding LENZ Therapeutics (NASDAQ: $LENZ) to the PRISM Emerging Biotech Index. With FDA approval secured and commercial launch underway for its presbyopia treatment, LENZ brings a de-risked, commercial-stage asset with early prescriber traction and global expansion underway. The addition strengthens our exposure to ophthalmology and companies transitioning from clinical to commercial stages. #LENZTherapeutics https://prismmarketview.com/companies/lenz-therapeutics-inc/

1 · Reply

stockpricequestioner Mar. 31 at 8:48 PM

$LENZ anyone else buying now?

3 · Reply

jGoooo Mar. 30 at 5:32 PM

$LENZ

0 · Reply

CEOBuysDisclosures Mar. 30 at 2:50 PM

$LENZ CEO purchased 28,089 shares at $8.95 for a total of $251,411. Schimmelpennink Evert B. now owns 77,289 shares. https://ceo-buys.com

3 · Reply

philipv777 Mar. 30 at 2:15 PM

$LENZ C-suite purchases https://ir.lenz-tx.com/sec-filings

3 · Reply

Lunr2024 Mar. 28 at 9:34 PM

$LENZ The stock price drop provided me with a lower buying opportunity, which made me happy; only those who sell stocks at low prices would be unhappy. I want to buy more; I have plenty of patience. According to the earnings call, in early 2027, the company will receive approvals from multiple countries, meaning it will receive several milestone payments and potential sales royalties.

0 · Reply

roblake29 Mar. 27 at 11:14 PM

$LENZ Sorry to investors here, but I have revaluated Lenz on the basis of weak Q4 results and a reassessment of the market for VIZZ. I have to admit my bullish take on the company was poor, with the stock dropping 50% since then. https://seekingalpha.com/article/4886734-lenz-therapeutics-q4-results-highlight-a-worrying-lack-of-market-demand-rating-downgrade

5 · Reply

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 17, 2026, 8:00 AM EDT - 22 days ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

Mar 10, 2026, 8:00 AM EDT - 4 weeks ago

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

Feb 23, 2026, 8:00 AM EST - 6 weeks ago

LENZ Therapeutics to Present at Upcoming Investor Conferences

Jan 30, 2026, 1:02 PM EST - 2 months ago

New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug

Jan 14, 2026, 8:30 AM EST - 3 months ago

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Jan 7, 2026, 5:08 PM EST - 3 months ago

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Jan 5, 2026, 8:00 AM EST - 3 months ago

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

Dec 1, 2025, 8:30 AM EST - 4 months ago

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

Nov 5, 2025, 8:00 AM EST - 5 months ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Oct 29, 2025, 8:00 AM EDT - 5 months ago

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

Sep 30, 2025, 8:05 AM EDT - 6 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 30, 2025, 8:00 AM EDT - 6 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Aug 25, 2025, 8:00 AM EDT - 8 months ago

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

Jul 31, 2025, 4:05 PM EDT - 8 months ago

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

Jul 30, 2025, 8:00 AM EDT - 9 months ago

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 28, 2025, 8:00 AM EDT - 9 months ago

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

Jul 7, 2025, 8:00 AM EDT - 9 months ago

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

May 9, 2025, 9:03 AM EDT - 11 months ago

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 7, 2025, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

Apr 30, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Mar 19, 2025, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

LENZ Therapeutics to Host Commercial Day on April 15, 2025

Feb 24, 2025, 8:00 AM EST - 1 year ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Oct 28, 2024, 1:51 PM EDT - 1 year ago

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

Oct 27, 2024, 9:00 PM EDT - 1 year ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Oct 21, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

ABOS

Aug 14, 2024, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

Aug 7, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 10, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

May 8, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 1, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Apr 3, 2024, 7:49 AM EDT - 2 years ago

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

Apr 2, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Mar 21, 2024, 4:30 PM EDT - 2 years ago

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

philipv777 Apr. 8 at 7:23 PM

$LENZ https://ir.lenz-tx.com/sec-filings/content/0001642575-26-000004/primary_doc.html

0 · Reply

JRobb66 Apr. 6 at 8:43 AM

$LENZ why is this stock in the toilet? Thought it had great expectations with a small float

2 · Reply

philipv777 Apr. 3 at 1:44 PM

$LENZ interesting off label use. The guy sounds like a set up for RD but good to see ophthalmologists are thinking about this drug

2 · Reply

prismmarketview Apr. 2 at 1:53 PM

1 · Reply

stockpricequestioner Mar. 31 at 8:48 PM

$LENZ anyone else buying now?

3 · Reply

jGoooo Mar. 30 at 5:32 PM

$LENZ

0 · Reply

CEOBuysDisclosures Mar. 30 at 2:50 PM

$LENZ CEO purchased 28,089 shares at $8.95 for a total of $251,411. Schimmelpennink Evert B. now owns 77,289 shares. https://ceo-buys.com

3 · Reply

philipv777 Mar. 30 at 2:15 PM

$LENZ C-suite purchases https://ir.lenz-tx.com/sec-filings

3 · Reply

Lunr2024 Mar. 28 at 9:34 PM

0 · Reply

roblake29 Mar. 27 at 11:14 PM

5 · Reply

Max_Regards Mar. 27 at 2:07 PM

$LENZ shorts will start covering soon if market continues to tank in my opinion.

4 · Reply

anachartanalyst Mar. 26 at 4:02 PM

$LENZ https://anachart.com/wp-content/uploads/ana_temp/1774540912_soc-img.jpg

0 · Reply

SirRahal Mar. 26 at 2:34 PM

$LENZ Lol, this thing can't even hold $9.... This is a shorts wet dream.... A stock that does nothing but drop and the whole market is read.... Bulls are in trouble. The company needs to make some big statements soon but don't think that will happen just after ER. I'm guessing this stock will stay red for the next month.

1 · Reply

Max_Regards Mar. 26 at 12:04 PM

$LENZ investor relations is officially unresponsive to any emails now. Not a great sign, if Nico is right and the top execs here even step slightly out of line I will be the first to approach litigation and a class action lawsuit. Anyone else have luck getting a response from investor relations?

6 · Reply

philipv777 Mar. 25 at 6:22 PM

$LENZ I keep asking, how much lower can this thing go? And I remember Peter lynch in his talk: https://youtu.be/Laex0QLG9jc?si=iu16EueRa6nWOV0O

0 · Reply

MJPTrades Mar. 25 at 4:48 PM

$LENZ drug is already approved, first in class, and doing well considering it’s kind of a new market, margins are strong, and it’s basically trading at cash value? Right above book value? I’m confused am I missing something here? I don’t have a position yet but how much lower can this possibly go? I understand that expenses are going up because they are commercializing and numbers with sales and prescriptions weren’t as high as the market wanted I guess but I feel it can’t slip much lower than it is right now no? For whatever reason the market just doesnt like to give certain niches value until their market is 100% validated I guess Can’t tell if we’re close to bottom or if price will continue to go down to under book value/slightly under book value before it starts making its way up

4 · Reply

Dreamit2 Mar. 25 at 4:00 PM

$LENZ You know, before the FDA approval the stock price was continually going up, but then after they got approved, it started languishing, not too long after. Makes me think the competition hires basement dwellers to try to suppress the price with huge short selling.

1 · Reply

DanteDraper8 Mar. 25 at 3:59 PM

$LENZ

0 · Reply

DanteDraper8 Mar. 25 at 3:58 PM

$LENZ

0 · Reply

NYTWben Mar. 25 at 1:38 PM

$LENZ Bank of America maintains their buy rating with at $29 target

4 · Reply

PeterV9764 Mar. 25 at 12:12 PM

$LENZ https://seekingalpha.com/news/4568182-lenz-outlines-2026-acceleration-strategy-while-expanding-vizz-sales-force-to-117-reps?share_source=shared_news

1 · Reply

Dreamit2 Mar. 25 at 1:21 AM

$LENZ Go to YouTube to... X gen investor. Scroll down to about the 7 month mark. Maybe 5 or 6 frames down and you can see the presentation on Lenz therapeutic. If anybody knows how to post that it would be good.

2 · Reply

Market Cap	301.31M
Revenue (ttm)	19.09M
Net Income (ttm)	-82.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-430.23%
Debt to Equity Ratio	0.00

Volume	491,540
Avg Vol	1,018,206
Day's Range	N/A - N/A
Shares Out	31.35M
Stochastic %K	78%
Beta	0.66
Analysts	Strong Sell
Price Target	$38.33